|
| Dihydroergocryptine | Pramipexole |
| No. of patients and gender (M/F) | 56 (29/27) | 60 (36/24) |
| Age (years) (mean ± SD) | 59.18 ± 9.74 | 58.17 ± 9.57 |
| Main sign | ||
| Tremor | 30 (53.6%) | 39 (65.0%) |
| Bradykinesia | 10 (17.9%) | 8 (13.3%) |
| Rigidity | 16 (28.6%) | 13 (21.7%) |
| Hoehn & Yahr stage (n, %) | ||
| Stage 1 | 1 (1.8%) | 4 (6.6%) |
| Stage 1.5 | 3 (5.4%) | 5 (8.3%) |
| Stage 2 | 27 (48.2%) | 20 (33.3%) |
| Stage 2.5 | 12 (21.4%) | 14 (23.3%) |
| Stage 3 | 9 (16.1%) | 11 (18.3%) |
| Stage 4 | 4 (7.1%) | 5 (8.3%) |
| Stage 5 | 0 | 1 (1.7%) |
| UPDRS (mean ± SD) | ||
| Total score | 51.42 ± 20.04 | 49.98 ± 20.34 |
| Mentation, behaviour and mood | 2.25 ± 2.06 | 2.46 ± 2.02 |
| Activities of daily living | 14.25 ± 6.78 | 12.61 ± 6.75 |
| Motor examination | 30.7 ± 13.32 | 30.86 ± 13.54 |
| Treatment complications | 4.22 ± 3.12 | 4.05 ± 3.14 |
| Schwab & England scale (n, %) | ||
| 10% | 0 | 1 (1.7%) |
| 20% | 1 (1.8%) | 0 |
| 30% | 0 | 1 (1.7%) |
| 40% | 1 (1.8%) | 1 (1.7%) |
| 50% | 1 (1.8%) | 1 (1.7%) |
| 60% | 2 (3.6%) | 1 (1.7%) |
| 70% | 1 (1.8%) | 5 (8.3%) |
| 80% | 13 (23.2%) | 8 (13.3%) |
| 90% | 17 (30.4%) | 15 (25.0%) |
| 100% | 20 (35.7%) | 27 (45.0%) |